Serbia to invest in antenatal genetic testing:
This article was originally published in Clinica
Serbia has earmarked over E2m ($2.6m) for the procurement of diagnostic equipment for detecting genetic abnormalities in the early stages of pregnancy. This follows a donation to the country of E2.5m by the European Agency for Reconstruction (EAR). Current capacities for diagnosing abnormalities antenally meet only one-third of needs, according to Matthias Reinicke, programme manager at EAR. The remaining funding will be used for training.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.